| Evaluating the effects of SARS-CoV-2 spike mutation D614G on transmissibility and pathogenicity E Volz, V Hill, JT McCrone, A Price, D Jorgensen, Á O’Toole, J Southgate, ... Cell 184 (1), 64-75. e11, 2021 | 1066 | 2021 |
| SARS-CoV-2 evolution during treatment of chronic infection SA Kemp, DA Collier, RP Datir, IATM Ferreira, S Gayed, A Jahun, ... Nature 592 (7853), 277-282, 2021 | 911 | 2021 |
| Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity B Meng, A Abdullahi, IATM Ferreira, N Goonawardane, A Saito, I Kimura, ... Nature 603 (7902), 706-714, 2022 | 821 | 2022 |
| Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B. 1.617. 2) compared with alpha (B. 1.1. 7) variants of concern: a cohort study KA Twohig, T Nyberg, A Zaidi, S Thelwall, MA Sinnathamby, S Aliabadi, ... The Lancet Infectious Diseases 22 (1), 35-42, 2022 | 801 | 2022 |
| Screening of healthcare workers for SARS-CoV-2 highlights the role of asymptomatic carriage in COVID-19 transmission L Rivett, S Sridhar, D Sparkes, M Routledge, NK Jones, S Forrest, ... elife 9, e58728, 2020 | 593 | 2020 |
| Virus genomes reveal factors that spread and sustained the Ebola epidemic G Dudas, LM Carvalho, T Bedford, AJ Tatem, G Baele, NR Faria, DJ Park, ... Nature 544 (7650), 309-315, 2017 | 435 | 2017 |
| Rapid implementation of SARS-CoV-2 sequencing to investigate cases of health-care associated COVID-19: a prospective genomic surveillance study LW Meredith, WL Hamilton, B Warne, CJ Houldcroft, M Hosmillo, ... The Lancet infectious diseases 20 (11), 1263-1271, 2020 | 432 | 2020 |
| Norovirus gene expression and replication LG Thorne, IG Goodfellow Journal of General Virology 95 (2), 278-291, 2014 | 340 | 2014 |
| Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B. 1.1. 7: an ecological study MS Graham, CH Sudre, A May, M Antonelli, B Murray, T Varsavsky, ... The Lancet Public Health 6 (5), e335-e345, 2021 | 336 | 2021 |
| Improvements to the ARTIC multiplex PCR method for SARS-CoV-2 genome sequencing using nanopore JR Tyson, P James, D Stoddart, N Sparks, A Wickenhagen, G Hall, ... BioRxiv, 2020 | 335 | 2020 |
| Identification of a cis-Acting Replication Element within the Poliovirus Coding Region I Goodfellow, Y Chaudhry, A Richardson, J Meredith, JW Almond, ... Journal of virology 74 (10), 4590-4600, 2000 | 331 | 2000 |
| Furin cleavage of SARS-CoV-2 Spike promotes but is not essential for infection and cell-cell fusion G Papa, DL Mallery, A Albecka, LG Welch, J Cattin-Ortolá, J Luptak, ... PLoS pathogens 17 (1), e1009246, 2021 | 294 | 2021 |
| Calicivirus translation initiation requires an interaction between VPg and eIF4E I Goodfellow, Y Chaudhry, I Gioldasi, A Gerondopoulos, A Natoni, ... EMBO reports 6 (10), 968-972, 2005 | 279 | 2005 |
| A thermostable, closed SARS-CoV-2 spike protein trimer X Xiong, K Qu, KA Ciazynska, M Hosmillo, AP Carter, S Ebrahimi, Z Ke, ... Nature structural & molecular biology 27 (10), 934-941, 2020 | 276 | 2020 |
| Evolution of enhanced innate immune evasion by SARS-CoV-2 LG Thorne, M Bouhaddou, AK Reuschl, L Zuliani-Alvarez, B Polacco, ... Nature 602 (7897), 487-495, 2022 | 265 | 2022 |
| Longitudinal analysis reveals that delayed bystander CD8+ T cell activation and early immune pathology distinguish severe COVID-19 from mild disease L Bergamaschi, F Mescia, L Turner, AL Hanson, P Kotagiri, BJ Dunmore, ... Immunity 54 (6), 1257-1275. e8, 2021 | 264 | 2021 |
| Norovirus regulation of the innate immune response and apoptosis occurs via the product of the alternative open reading frame 4 N McFadden, D Bailey, G Carrara, A Benson, Y Chaudhry, A Shortland, ... PLoS pathogens 7 (12), e1002413, 2011 | 263 | 2011 |
| Resurgence of Ebola virus disease in Guinea linked to a survivor with virus persistence in seminal fluid for more than 500 days B Diallo, D Sissoko, NJ Loman, HA Bah, H Bah, MC Worrell, LS Conde, ... Clinical infectious diseases 63 (10), 1353-1356, 2016 | 255 | 2016 |
| Advances in norovirus biology SM Karst, CE Wobus, IG Goodfellow, KY Green, HW Virgin Cell host & microbe 15 (6), 668-680, 2014 | 230 | 2014 |
| Experimental treatment of Ebola virus disease with TKM-130803: a single-arm phase 2 clinical trial J Dunning, F Sahr, A Rojek, F Gannon, G Carson, B Idriss, T Massaquoi, ... PLoS medicine 13 (4), e1001997, 2016 | 191 | 2016 |
Dalan BaileyThe Pirbright InstituteVerified email at pirbright.ac.uk
